Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Fmr LLC

FMR LLC cut its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 17.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,091,648 shares of the company's stock after selling 2,709,019 shares during the quarter. FMR LLC owned about 10.50% of Vaxcyte worth $1,071,682,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Diversified Trust Co acquired a new position in Vaxcyte in the 4th quarter valued at about $1,433,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Vaxcyte by 23.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock valued at $2,163,000 after purchasing an additional 4,962 shares during the last quarter. TimesSquare Capital Management LLC increased its holdings in shares of Vaxcyte by 53.7% in the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock valued at $33,860,000 after purchasing an additional 144,516 shares during the period. Principal Financial Group Inc. raised its stake in shares of Vaxcyte by 186.2% during the third quarter. Principal Financial Group Inc. now owns 52,702 shares of the company's stock worth $6,022,000 after purchasing an additional 34,287 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Vaxcyte by 70.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock worth $49,418,000 after purchasing an additional 246,049 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Vaxcyte Stock Performance

PCVX stock traded up $3.16 during midday trading on Friday, hitting $31.20. 4,052,649 shares of the stock were exchanged, compared to its average volume of 1,197,573. The stock has a market cap of $4.02 billion, a price-to-earnings ratio of -6.78 and a beta of 1.26. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06. The stock's 50-day moving average price is $66.40 and its 200-day moving average price is $85.55.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14. Research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on PCVX. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Needham & Company LLC reissued a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Bank of America lowered their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. The Goldman Sachs Group cut their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Guggenheim restated a "buy" rating and issued a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $136.50.

Insider Activity

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total value of $692,080.00. Following the transaction, the chief financial officer now directly owns 109,491 shares in the company, valued at approximately $9,472,066.41. This represents a 6.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Teri Loxam sold 6,250 shares of the firm's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the sale, the director now directly owns 7,175 shares in the company, valued at $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,250 shares of company stock worth $3,170,738 over the last ninety days. 3.10% of the stock is currently owned by insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.